Medinol v. Guidant patent trial
This article was originally published in The Gray Sheet
Executive Summary
July 10 trial date set for the U.S. District Court for the Southern District of New York to assess the validity of Medinol's '381 patent related to the flexibility of its coronary stents. If Medinol's claims hold, the jury will set damages based on Guidant's infringement of the Israeli firm's patent. Medinol was granted summary judgment on Feb. 10 that Guidant violated its patent (1"The Gray Sheet" March 6, 2006, p. 4). Once started, the trial is expected to conclude within seven trial days. The Israeli firm is asking for royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform...
You may also be interested in...
Medinol Strikes Twice: Guidant Entanglement May Affect Boston Scientific
Medinol is seeking royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform in an upcoming patent infringement trial that could begin by April
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.